Doctors are now refusing to see pharmaceutical reps in China, for fear of being implicated in the growing drug scandal there. Big Pharma is taking a hit to be sure, with drug sales in China waning sharply. GlaxoSmithKline Plc is getting hardest hit with sales growth expected to drop sharply and perhaps even reverse for the third quarter of this year. And in a market where pharmaceutical sales are expected to hit $1 trillion by 2020, from $357 billion in 2011, any reversal in growth can be devastating for a company’s future intentions. Just as it can be a disaster for investors backing a company like Glaxo, if doctors’ fears of accepting visits from pharmaceutical representatives remain.
Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:
Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.
Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:
Claim your free copy of Dr. Mark Skousen's and Tim Plaehn's new report:
High Yield Havens: 3 Dividend Plays To Safely Hold Forever
Access your free report below:
*By submitting your email, you'll receive this free report, along with complimentary access to Skousen CAFE' and Investors Alley, along with associated financial content and special offers. We value your privacy. You will not be spammed, ever. Period.